Israel Englander Caladrius Biosciences, Inc. Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.15 - $1.57 $74,638 - $101,897	-64,903 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.4 - $1.9 $28,697 - $38,946	20,498 Added 46.16%	64,903 $104,000
Q1 2021 May 17, 2021	BUY	$1.44 - $2.89 $63,943 - $128,330	44,405 New	44,405 $86,000
Q4 2020 Feb 16, 2021	SELL	$1.39 - $1.87 $34,284 - $46,123	-24,665 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.6 - $3.0 $39,464 - $73,995	24,665 New	24,665 $44,000

Q2 2018 Aug 14, 2018	SELL	$3.8 - $8.64 $40,375 - $91,800	-10,625 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.7 - $6.09 $39,312 - $64,706	10,625 New	10,625 $62,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.